Business Focus and Strategy - Berry Genomics reported a significant shift in its main business focus from automotive parts to high-throughput sequencing-based genetic testing services and equipment sales following a major asset restructuring completed in August 2017[22]. - The company aims to expand its market presence, leveraging advancements in non-invasive prenatal testing and other genetic testing technologies[5]. - The company is positioned within a key emerging industry, as highlighted in the "14th Five-Year Plan" which emphasizes health technology and biotechnological advancements[34]. - The company aims to become a gene technology firm focused on clinical commercialization and health big data development, leveraging existing testing platforms to accumulate genetic data[98]. - The company plans to enhance its existing non-invasive products and services to assist clinical decision-making in precision medicine[99]. Financial Performance - The company's operating revenue for 2022 was ¥1,368,007,211.88, a decrease of 3.81% compared to ¥1,422,180,921.29 in 2021[24]. - The net profit attributable to shareholders was -¥254,778,590.81, representing a decline of 129.91% from -¥110,818,562.80 in the previous year[24]. - The cash flow from operating activities was ¥21,178,809.92, down 77.48% from ¥94,031,452.65 in 2021[24]. - The basic and diluted earnings per share were both -¥0.82, a decrease of 164.52% compared to -¥0.31 in 2021[24]. - The company reported a total revenue of 1,055.04 million CNY, representing a 2.25% increase compared to the previous year[172]. Research and Development - The company has committed to ongoing research and development in new products and technologies to enhance its service offerings in genetic testing[5]. - The company is actively involved in the development of new technologies and products, including third-generation sequencing techniques for various genetic disorders, enhancing diagnostic accuracy[40]. - The company has developed over 1 PB of gene data annually, enhancing its capabilities in clinical information interpretation and artificial intelligence algorithms[54]. - The company has established a robust research service platform utilizing leading sequencing technologies, including Illumina NovaSeq6000 and PacBio Sequel, to support various scientific research fields[43]. Market Trends and Opportunities - The gene sequencing industry is rapidly growing, supported by national policies and increasing public awareness of disease prevention[34]. - The high-throughput sequencing market is expected to continue rapid growth, driven by decreasing sequencing costs and increasing application scenarios in reproductive health, oncology, and consumer-grade genetic testing[37]. - The Beijing Medical Insurance Bureau included 16 assisted reproductive technologies, such as artificial insemination and embryo transfer, in the Class A reimbursement scope, which is expected to enhance the penetration of gene sequencing products and services[37]. Corporate Governance and Management - The company operates independently from its controlling shareholders, ensuring no overlap in business operations or financial dealings[111]. - The company has established a complete independent financial system, with separate financial management and decision-making processes, ensuring no interference from shareholders[113]. - The company has a robust organizational structure with clearly defined responsibilities, operating independently from its major shareholders[113]. - The company has conducted multiple shareholder meetings, with participation rates of 32.44% and 19.60% in the respective meetings held in 2022[114]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,438, with 1,434 in major subsidiaries[137]. - The educational background of employees includes 21 with PhDs, 309 with master's degrees, and 724 with bachelor's degrees, reflecting a highly educated workforce[137]. - The company has established a competitive salary system to align with business development and market standards, integrating performance management with salary incentives[138]. - The company has a detailed regulation on related party transactions, ensuring strict compliance and risk control[146]. Risks and Challenges - Future operational risks and challenges are outlined in the management discussion, emphasizing the need for investor awareness regarding potential uncertainties[5]. - The company faces risks from industry policy changes, intensified market competition, and potential declines in service prices[101]. - The rapid expansion of accounts receivable poses a risk of bad debts, which could impact the company's operational development[104]. - The company is exposed to financial risks, including potential declines in gross margin due to market competition and regulatory uncertainties[104]. Product and Service Offerings - The company focuses on gene detection services based on high-throughput sequencing technology, targeting areas such as reproductive health, genetic disease detection, and tumor detection[38]. - The company provides comprehensive genetic testing services covering three levels of birth defect prevention, including carrier screening for 153 diseases and pre-implantation genetic testing[39]. - The company offers non-invasive prenatal testing (NIPT) for chromosomal aneuploidy screening and a more advanced NIPT Plus for 100 chromosomal and genomic diseases[39]. - The company has developed a comprehensive cancer screening product "Laisining" for liver cancer, validated by a prospective cohort study involving over 10,000 participants, and included in the national early screening strategy[42]. Shareholder and Equity Information - The company reported a total shareholding of 58.45 million shares at the end of the reporting period, down from 64.11 million shares at the beginning, indicating a decrease of approximately 8.3%[117]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., holds 12.41% of the shares, totaling 44,002,000 shares, with no changes during the reporting period[199]. - The total number of shareholders at the end of the reporting period was 41,358, with a slight decrease from the previous month[198]. - The company has maintained a consistent shareholder base without any significant changes in ownership during the reporting period[200].

Group 1: Restructuring Overview - The restructuring is led by the actual controller, with the project being selected after thorough comparison [2] - The actual controller has a dedicated team for related projects [2] - The restructuring aims to develop a dual-main business model, contingent on the future development of both business segments [3] Group 2: Old Ken Medical's Operations - Old Ken Medical withdrew its IPO application in May 2013 due to market changes and strategic needs [3] - The company is collaborating with the UK New Helix Group to establish a nationwide medical disinfection service outsourcing system [3] - The business performance of Old Ken Medical in January and February of this year has been reported as good [4] Group 3: Management and Financing Post-Reorganization - Post-reorganization, Liu Xia is proposed to be nominated as a candidate for the board of directors and to serve as the deputy general manager of Tianxing Instrument [4] - Daily operations of Old Ken Medical will primarily be managed by its own team, with Tianxing Instrument appointing directors and financial leaders [4] - Financing will mainly support Old Ken Medical, while Tianxing Instrument's significant expenditures will be related to relocation and new factory construction [4] Group 4: Risks and Future Plans - The reorganization faces risks such as regulatory approval, integration challenges, and inherent risks of Old Ken Medical [4][5] - The timeline for completing the reorganization is uncertain and depends on the China Securities Regulatory Commission's review [4][5]

证券代码：000710 证券简称：天兴仪表 编号：2015-04 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 大成基金：李林益 | | | 人员姓名 | 博时基金：甘传琦 | | | 时间 | 2015 年 4 月 22 日 | | | 地点 | 董秘办公室 | | | 上市公司接待人 | 董事会秘书：叶秀松 | | | 员姓名 | 证券事务代表：左炯 | | | 投资者关系活动 | 1. | 天兴仪表车用零部件这一块业务一年有多少利润？ | | 主要内容介绍 | | 近年由于主 ...

证券代码：000710 证券简称：天兴仪表 编号：2015-02 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 华创证券有限责任公司：彭婷 | | | 人员姓名 | | | | 时间 | 2015 年 3 月 26 日 | | | 地点 | 董秘办公室 | | | 上市公司接待人 | 董事会秘书：叶秀松 | | | 员姓名 | 证券事务代表：左炯 | | | | 1. | 天兴集团股权被冻结对公司重组的影响？ | | | | 天兴集团所持被冻结的股份在冻结 ...

Group 1: Company Overview - Chengdu Tianxing Instrument Co., Ltd. focuses on the development, production, and sales of hospital infection control equipment and provides comprehensive solutions for Central Sterile Supply Departments (CSSD) [3] - The company will maintain dual business operations in automotive instruments and hospital infection control equipment after restructuring [3][4] Group 2: Restructuring and Business Strategy - The restructuring plan is currently under review by the China Securities Regulatory Commission, and no new projects are being considered at this time [4] - The major shareholder's frozen shares do not affect the company's normal operations, and efforts are being made to resolve financial disputes [4][5] - Tianxing Group holds a controlling stake of 58.86% in Tianxing Instrument, with a market value of approximately 1.188 billion yuan as of March 6, 2015 [4][5] Group 3: Management and Operations - Post-restructuring, the original management team of Aoken Medical will continue to manage daily operations, with Tianxing Instrument appointing directors and financial leaders [5] - Aoken Medical has ongoing contracts and orders, details of which are available in the company's public announcements [5]

Group 1: Company Restructuring and Debt Situation - The company has temporarily withdrawn its major asset restructuring application due to unresolved issues regarding the freezing of shares held by the controlling shareholder [2] - As of May 27, 2015, the China Securities Regulatory Commission issued a notice to terminate the review of the company's administrative license application [2] - The controlling shareholder holds 88.96 million shares, of which 79.02 million shares are currently frozen due to a financial loan dispute involving approximately 278 million yuan, nearing 300 million yuan with interest [2] Group 2: Business Operations and Future Prospects - Despite poor operational performance, the company maintains a clean financial record without external guarantees or contingent liabilities, primarily relying on bank loans [2] - If relocation compensation funds are fully in place, the company's financial pressure will ease, leading to a reduction in debt [3] - The company is exploring potential cooperation with other firms if the share freezing issue remains unresolved in the short term [3] - The automotive instrument industry is facing significant challenges, while the medical equipment sector shows higher profit margins and promising prospects [3] - The timeline for restructuring outcomes remains uncertain, dependent on the resolution of the share freezing issue and the willingness of potential partners to wait [3]

编号：2015-12 证券代码：000710 证券简称：天兴仪表 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 景顺长城基金管理有限公司：刘晓明 | | | 人员姓名 | 长城基金管理有限公司：谭小兵 | | | 时间 | 2015 年 12 月 1 日 | | | | | | | 地点 | 董秘办公室 | | | 上市公司接待人 | 董事会秘书：顾中国 | | | 员姓名 | 证券事务代表：左炯 | | | | 1. | 公司未来转型是否主要考虑医疗方向？ | | 投资者 ...

编号：2015-11 证券代码：000710 证券简称：天兴仪表 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 类别 | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 上海理成资产管理有限公司：张伟 | 汇添富基金管理股份有限公司：林小伟 | | 时间 | 2015 年 11 月 2 ...

证券代码：000710 证券简称：天兴仪表 编号：2015-07 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------| | | | | | 投资者关系活动 类别 | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 广州金骏投资控股有限公司：刘保瑶 浙 ...

编号：2015-10 证券代码：000710 证券简称：天兴仪表 成都天兴仪表股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 类别 | √ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | ...